AR132055A1 - Inhibidores duales de cdk8/19 y métodos de uso de los mismos - Google Patents
Inhibidores duales de cdk8/19 y métodos de uso de los mismosInfo
- Publication number
- AR132055A1 AR132055A1 ARP240100545A ARP240100545A AR132055A1 AR 132055 A1 AR132055 A1 AR 132055A1 AR P240100545 A ARP240100545 A AR P240100545A AR P240100545 A ARP240100545 A AR P240100545A AR 132055 A1 AR132055 A1 AR 132055A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutically acceptable
- cdk8
- inhibitors
- dual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (1a), o una sal o estereoisómero farmacéuticamente aceptable del mismo. Un compuesto caracterizado porque es seleccionado de un compuesto que se encuentra en la Tabla 1 o la Tabla 2, o una sal o estereoisómero farmacéuticamente aceptable del mismo. Un compuesto de cualquiera de las reivindicaciones 1 - 26, o una sal o estereoisómero farmacéuticamente aceptable del mismo, caracterizado porque el compuesto es un inhibidor de CDK8. Una composición farmacéutica caracterizada porque comprende un compuesto de cualquiera de las reivindicaciones 1 - 27, o una sal o estereoisómero farmacéuticamente aceptable del mismo, y al menos un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023079857 | 2023-03-06 | ||
| CN2023138484 | 2023-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132055A1 true AR132055A1 (es) | 2025-05-21 |
Family
ID=92674120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100545A AR132055A1 (es) | 2023-03-06 | 2024-03-05 | Inhibidores duales de cdk8/19 y métodos de uso de los mismos |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN120826396A (es) |
| AR (1) | AR132055A1 (es) |
| TW (1) | TW202440093A (es) |
| WO (1) | WO2024183726A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1476535A (fr) * | 1965-05-10 | 1967-04-14 | Chimetron Sarl | Thiazolylbenzimidazole-glucosides et produits apparentés |
| GB201223265D0 (en) * | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
| CN112028815A (zh) * | 2019-06-03 | 2020-12-04 | 中国药科大学 | 吲哚类衍生物及其医药用途 |
| JP2023520400A (ja) * | 2020-04-03 | 2023-05-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | アルファ－１－アンチトリプシン欠損症（ａａｔｄ）を治療するためのアルファ－１－アンチトリプシンモジュレーターとしてのインドール誘導体 |
| UY39579A (es) * | 2020-12-22 | 2022-07-29 | Novartis Ag | COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS |
| WO2023241627A1 (en) * | 2022-06-15 | 2023-12-21 | Insilico Medicine Ip Limited | Cdk8/19 dual inhibitors and methods of use thereof |
-
2024
- 2024-03-05 CN CN202480015555.5A patent/CN120826396A/zh active Pending
- 2024-03-05 WO PCT/CN2024/080162 patent/WO2024183726A1/en not_active Ceased
- 2024-03-05 AR ARP240100545A patent/AR132055A1/es unknown
- 2024-03-05 TW TW113107915A patent/TW202440093A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202440093A (zh) | 2024-10-16 |
| CN120826396A (zh) | 2025-10-21 |
| WO2024183726A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132338A1 (es) | Inhibidores de ras | |
| AR133988A1 (es) | Inhibidores de ras-pi3k y usos de los mismos | |
| AR134265A1 (es) | Heterociclos y usos de los mismos | |
| AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
| AR132007A1 (es) | Compuestos y métodos para modular ras-pi3k | |
| AR131639A1 (es) | Inhibidores de kif18a y usos de los mismos | |
| MX2024009158A (es) | Inhibidores de parp7. | |
| AR128932A1 (es) | Inhibidores de bcl-xl | |
| AR130602A1 (es) | Inhibidores de tead y métodos de uso de los mismos | |
| AR133240A1 (es) | Compuestos, composiciones y métodos | |
| AR133241A1 (es) | Compuestos, composiciones y métodos | |
| DOP2025000009A (es) | Inhibidores de acc novedosos | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| AR131906A1 (es) | Compuestos terapéuticos | |
| AR132055A1 (es) | Inhibidores duales de cdk8/19 y métodos de uso de los mismos | |
| AR132166A1 (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| AR132838A1 (es) | Inhibidores de prmt5 y usos de los mismos | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR132818A1 (es) | Compuestos para la degradación de la cinasa egfr | |
| AR132983A1 (es) | Inhibidores keap1 y usos de los mismos | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| AR128868A1 (es) | Formulaciones de inhibidor de tyk2 y métodos para elaborarlas | |
| AR133286A1 (es) | Inhibidores ra2s heterocíclicos de igf-1r para el tratamiento de enfermedades | |
| AR134110A1 (es) | Inhibidores de ras | |
| AR132167A1 (es) | Inhibidores de fgfr2 y fgfr3 y usos de los mismos |